Renal System, Endocrinology, Type 2-Diabetes, Type 1-Diabetes
1. Apr 2020
Reduced O-GlcNAcylation and Tubular Hypoxia Contribute to the Antifibrotic Effect of SGLT2 Inhibitor Dapagliflozin in the Diabetic Kidney
Diabetic kidney disease is a worldwide epidemic, and therapies are incomplete. Clinical data suggest that improved renal outcomes by Na+-glucose cotransporter 2 inhibitor (SGLT2i) are partly beyond their antihyperglycemic effects; however, the mechanisms are still elusive. Here, we investigated the …
Read the publication
Journal:
Authors:
- Hodrea J,
- Balogh DB,
- Hosszu A,
- Lenart L,
- Besztercei B,
- koszegi S,
- Sparding N,
- Genovese F,
- Wagner LJ,
- Szabo AJ,
- Fekete A,